Chief Physician, Professor, Doctoral Supervisor, Director of the Department of Nuclear Medicine, Renji Hospital.
Affiliated HospitalRenji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
→
Research Areas : Biological mechanisms and clinical translation of PET/CT imaging technology; integrated diagnosis and treatment of PSMA in prostate cancer. Cutting-Edge Technologies: Over 20 years of clinical experience in nuclear medicine molecular imaging; pioneered the application of PET/CT for the differential diagnosis, staging, and efficacy evaluation of malignant tumors; led research on the detection rate and lesion distribution characteristics of Ga-PSMA-11 PET/CT in patients with biochemical recurrence after radical prostatectomy; spearheaded the publication of the "Chinese Expert Consensus on the Clinical Application of PSMA PET Imaging in Prostate Cancer (2025 Edition)"; promoted the application of 177Lu-PSMA RLT in prostate cancer.
Areas of Expertise: PSMA PET/CT diagnosis and radionuclide therapy for prostate cancer, radionuclide therapy for thyroid diseases, and radionuclide therapy for metastatic bone tumors. Academic Highlights: Member and Deputy Secretary-General of the Chinese Society of Nuclear Medicine, Deputy Head of the PET Group; Standing Committee Member and Secretary-General of the Chinese Medical Doctor Association's Nuclear Medicine Branch; Chairman-elect of the Shanghai Medical Association's Nuclear Medicine Branch; Vice President of the Shanghai Medical Doctor Association's Nuclear Medicine Branch; Principal investigator of national-level projects funded by the National Natural Science Foundation of China and the Ministry of Science and Technology; Published over 50 SCI papers in Q1 journals as corresponding author, including multiple articles in top journals such as Radiology, JNM, and EJNM.